医薬品リファレンス
Tisotumab vedotin
Tisotumab vedotin is a medicine in the class oncology. It is used for cervical cancer.
- 薬効分類: Oncology
- 効能・効果: cervical cancer
最終更新日 出典: US FDA label
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Oncology
- ATCコード
- L01FX23
- 一般的な剤形
- 注射剤
- 一般的な規格
- 40 mg/4 ml
- 既知の相互作用
- 7 (中等度: 7)
- 商品名
- 2
- 国・市場
- 2
何に使われるか
作用のしくみ
Tissue factor-directed antibody drug conjugate. The ADC binds TF-expressing cancer cells and is internalized. MMAE is then released by proteolytic cleavage, disrupting the microtubule network and causing cell cycle arrest and apoptotic cell death.
成人の通常用量（添付文書の要約）
Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy: 2 mg/kg (maximum 200 mg for patients ≥100 kg) IV infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity
妊娠と授乳
- 妊娠
- Unsafe Can cause fetal harm: no human data; its MMAE payload caused fetal deaths and malformations in rats below human exposure. Check pregnancy status before starting; contraception during and for 2 months after the last dose (men with female partners: 4 months).
- 授乳
- Unsafe No human milk data. The antibody is large and poorly absorbed, but the small MMAE payload might reach the infant. Do not breastfeed during treatment and for 3 weeks after the last dose.
報告されている副作用
- Hemoglobin decreased
- Peripheral neuropathy
- Conjunctival adverse reactions
- Nausea
- Fatigue
- Aspartate aminotransferase increased
警告（枠囲み警告）
- Ocular toxicity: can cause severe ocular toxicities, including changes in vision, severe vision loss and corneal ulceration. Conduct an ophthalmic exam (symptoms, visual acuity, slit lamp exam) before starting, before every cycle for the first nine cycles, and as clinically indicated. Adhere to required premedication and eye care. Withhold until improvement, then resume, reduce the dose, or permanently discontinue based on severity.
注意が必要な方
- Severe ocular adverse reactions (conjunctivitis, keratopathy, dry eye) occurred in 55% of patients; eye exams and eye care are required.
- Peripheral neuropathy occurred in 39% of patients; monitor and withhold, reduce or discontinue based on severity.
- Hemorrhage occurred in 51% of patients; permanently discontinue for pulmonary or CNS hemorrhage.
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (7)
- Chloramphenicol + Tisotumab vedotin Moderate
- Clarithromycin + Tisotumab vedotin Moderate
- Itraconazole + Tisotumab vedotin Moderate
- Ketoconazole + Tisotumab vedotin Moderate
- Mifepristone + Tisotumab vedotin Moderate
- Posaconazole + Tisotumab vedotin Moderate
- Tisotumab vedotin + Voriconazole Moderate
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Tisotumab vedotinの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- IV preparation and dilution
WebでPro+を14日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Tisotumab vedotin used for?
Tisotumab vedotin is a medicine in the class oncology. It is used for Cervical cancer.
What side effects have been reported with Tisotumab vedotin?
Hemoglobin decreased, Peripheral neuropathy, Conjunctival adverse reactions, Nausea, Fatigue, Aspartate aminotransferase increased. Serious warning: Ocular toxicity: can cause severe ocular toxicities, including changes in vision, severe vision loss and corneal ulceration.
Can Tisotumab vedotin be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: no human data; its MMAE payload caused fetal deaths and malformations in rats below human exposure. Check pregnancy status before starting; contraception during and for 2 months after the last dose (men with female partners: 4 months). Breastfeeding: Unsafe. No human milk data. The antibody is large and poorly absorbed, but the small MMAE payload might reach the infant. Do not breastfeed during treatment and for 3 weeks after the last dose.
What does Tisotumab vedotin interact with?
MediHelp lists 7 known interactions for Tisotumab vedotin. Moderate: 7. The most serious include Chloramphenicol, Clarithromycin, Itraconazole.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
